Stephane Boissel, President and CEO

Oct. 12 | 2:15pm | Oxford Biomedica Ballroom  

Paris, France 


In-person Presentation 

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The company also has a strategic collaboration with Intellia Therapeutics to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions